Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death in
the Western world. Owing to a lack of specific symptoms and no accessible precursor …

Introduction: Despite many efforts to improve the outcome of pancreatic ductal
adenocarcinoma (PDAC), its prognosis remains poor, which is mostly related to late …

Pancreatic ductal adenocarcinoma (PDAC) is an incidence rate nearly equal to its mortality
rate. The poor prognosis of the disease can be explained by the absence of effective …

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of
cancer death in the USA. The 5-year survival of< 5% has not changed in decades. In …

Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early
locoregional spread and distant metastases at diagnosis, leading to dismal prognosis and …

Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignancy with an overall 5-year
survival of 8% for all stages combined. The majority of patients present with stage IV disease …

Background: Pancreatic cancer is the fourth leading cause of cancer-related death in the
US. However, there is a growing belief that novel biological agents could improve survival of …

Background: Pancreatic adenocarcinoma is a leading cause of cancer deaths in the US.
Gemcitabine-based chemotherapy remains the cornerstone treatment for advanced …

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy
with a median 5-year survival of< 8%. At the time of diagnosis, a vast majority of pancreatic …